https://scholars.lib.ntu.edu.tw/handle/123456789/454616| Title: | CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions | Authors: | Kuo H.-W. Liu S.C. Tsou H.-H. Liu S.-W. Lin K.-M. SHAO-CHUN LU Hsiao M.-C. Hsiao C.-F. Liu C.-Y. Chen C.-H. Lu M.-L. Shen W.W. Tang H.-S. Liu S.-I. Chang L.-H. Wu H.-Y. Chang Y.-S. Yeh T.-K. Chen A.C. Liu Y.-L. |
Keywords: | CYP1A2; escitalopram; major depressive disorder; side effects; SNP | Issue Date: | 2013 | Publisher: | Future Medicine Ltd. | Journal Volume: | 14 | Journal Issue: | 10 | Start page/Pages: | 1191-1201 | Source: | Pharmacogenomics | Abstract: | Aim: The liver CYP1A2 enzyme may metabolize antidepressant escitalopram (S-CIT) to S-desmethylcitalopram (S-DCIT) and S-didesmethylcitalopram (S-DDCIT). This study tested whether genetic polymorphisms in the CYP1A2 gene are associated with the treatment responses to S-CIT. Materials & methods: Ten SNPs in CYP1A2 were selected and genotyped in 158 patients under S-CIT treatment. The serum levels of S-CIT and its metabolites were measured by HPLC. Results:CYP1A2 SNPs rs2069521, rs2069526, rs4646425 and rs4646427 are significantly associated with the metabolic ratios of S-DDCIT/S-DCIT (p = 0.002, 0.018, 0.008 and 0.004, respectively) at week 2 of treatment. Carriers of the allele types associated with higher S-DDCIT/S-DCIT ratios had more severe side effects. Conclusion: These results suggest that genetic variants in CYP1A2 may be indicators for S-CIT metabolism and that the fast metabolizers may experience more severe adverse reactions in the early stages of S-CIT treatment. Original submitted 27 December 2012; Revision submitted 15 May 201. ? 2013 Future Medicine Ltd. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84880485709&doi=10.2217%2fpgs.13.105&partnerID=40&md5=b63d94269f2ab871d1790a54ffc33230 https://scholars.lib.ntu.edu.tw/handle/123456789/454616 |
ISSN: | 1462-2416 | DOI: | 10.2217/pgs.13.105 | SDG/Keyword: | cytochrome P450 1A2; dinorcitalopram; drug metabolite; escitalopram; norcitalopram; unclassified drug; antidepressant agent; citalopram; cytochrome P450 1A2; adverse outcome; allele; article; Clinical Global Impression scale; cohort analysis; controlled study; CYP1A2 gene; disease severity; drug blood level; drug metabolism; drug response; drug safety; fatigue; female; gene locus; genetic association; genetic variability; genotype; Hamilton scale; haplotype; heterozygote; high performance liquid chromatography; human; major clinical study; major depression; male; nausea; patient compliance; single nucleotide polymorphism; smoking; vomiting; xerostomia; adverse drug reaction; Depressive Disorder, Major; gene linkage disequilibrium; genetic polymorphism; genetics; middle aged; pathology; single nucleotide polymorphism; Antidepressive Agents; Citalopram; Cytochrome P-450 CYP1A2; Depressive Disorder, Major; Drug-Related Side Effects and Adverse Reactions; Female; Genetic Association Studies; Haplotypes; Humans; Linkage Disequilibrium; Male; Middle Aged; Polymorphism, Genetic; Polymorphism, Single Nucleotide [SDGs]SDG3 |
| Appears in Collections: | 生物化學暨分子生物學科研究所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.